Drug pricing is one area where there may be potential future policy changes that impact community oncologists, said Dan Todd, JD, principal at Todd Strategy.
Drug pricing is one area where there may be potential future policy changes that impact community oncologists, said Dan Todd, JD, principal at Todd Strategy.
Transcript (slightly modified)
What big policy issues and changes, other than the Affordable Care Act, should community oncologists keep an eye on?
I think drug pricing is still a really big issue, I don’t think it is necessarily going to go away, and I think that it’ll likely be impacted in several different avenues. One is with faster approvals at the FDA, which will certain impact practices. I think the focus on cost and some of those drivers, so things like the 340B program, that the administration has turned its attention to. So, to me the impact of drug pricing and its bleed effect on market consolidation will continue to be a big issue.
With so much bipartisan interest in drug pricing, do you expect to see any legislation in this area, and what might it look like?
I think that there will always be a focus on cost pressures. I think it’s a really complicated issue, particularly for Congress. There’s obviously a lot of politics around it and there’s a lot of support for innovation, generally, and reimbursement rates impact where investments are made and I think they’re aware of that.
I do think that particularly with some of the more novel drug launches, that are going to be happening, with some fairly high prices, the dialogue will continue. I don’t see necessarily an opportunity for broad fundamental changes. I think that healthcare has been a difficult issue for the Republicans in Congress and we’re very quickly running out of a legislating window so I think a lot is going to happen at the administration level.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More